FDA To Use New Discipline Review Letters In Communicating ANDA Deficiencies To Generic Drugmakers
Executive Summary
FDA will be issuing discipline review letters and information request letters to generic drug applicants to communicate shortcomings in ANDAs. Under GDUFA II, the US agency agreed to send out these letters at the mid-point of the review clock.
You may also be interested in...
In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?
MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts tell the Pink Sheet.
In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?
MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts tell the Pink Sheet.
US FDA To Generic Sponsors: Don't Call Us, We'll GDUFA You
FDA says there are only a few situations where the ANDA status call to the project manager is necessary, and industry seems to agree that review system improvements make the once-contentious check-in process less necessary.